Kymera Therapeutics

KYMRKymera Therapeutics

About Kymera Therapeutics

Kymera Therapeutics (NASDAQ:KYMR) is a biotechnology firm focused on pioneering advances in targeted protein degradation (TPD) to address previously untreatable diseases. Utilizing its proprietary Pegasus platform, Kymera aims to harness the body's innate protein recycling machinery to degrade disease-causing proteins with a high degree of selectivity. The company's pipeline includes projects targeting various disorders, with a strong emphasis on immuno-oncology, inflammatory diseases, and fibrosis. Kymera is on a mission to transform the treatment landscape for patients through innovative science and strategic partnerships, aspiring to deliver a new class of highly effective therapies across multiple disease areas.

What is KYMR known for?

Snapshot

Public US

Ownership

2015

Year founded

207

Employees

Massachusetts, United States

Head office

Loading Map...

Operations

All Locations

United States

Products and/or services of Kymera Therapeutics

Targeted Protein Degradation Platform: A technology platform designed to harness the body's natural protein degradation system to selectively eliminate disease-causing proteins.
KT-474: An orally bioavailable IRAK4 degrader targeting immune-inflammatory diseases such as atopic dermatitis and hidradenitis suppurativa.
KT-333: A STAT3 degrader aimed at treating hematologic malignancies and solid tumors by disrupting critical cancer cell signaling pathways.
KT-413: An IRAKIMiD bifunctional molecule targeting MYD88-mutant B-cell malignancies by combining IRAK4 degradation and IMiD therapy.
STAT3 Degrader Program: "Focused on developing selective degraders of STAT3 to combat various forms of cancer.
PI3Kd Degrader Program: Designed to selectively degrade PI3Kd, a protein kinase implicated in a wide range of hematologic malignancies.